The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells

Child's Nervous System

Volumn 27, Issue 6, 2011, Pages 897-901

  Nör, Carolina ^a,b,c   De Farias, Caroline Brunetto ^a,b,c   Abujamra, Ana Lucia ^a,b,c   Schwartsmann, Gilberto ^a,b,c   Brunetto, Algemir Lunardi ^a,b,c   Roesler, Rafael ^a,b,c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c National Institute for Translational Medicine INCT TM   (Brazil)

Author keywords

Brain tumors; Brain derived neurotrophic factor; Epigenetics; Histone deacetylase inhibitors; Medulloblastoma; Sodium butyrate

Indexed keywords

BUTYRIC ACID; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CYTOMETRY; DRUG EFFECT; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; PRIORITY JOURNAL;

BRAIN-DERIVED NEUROTROPHIC FACTOR; BUTYRATES; CELL LINE, TUMOR; CELL SURVIVAL; CEREBELLAR NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; MEDULLOBLASTOMA;

EID: 79959723261     PISSN: 02567040     EISSN: 14330350     Source Type: Journal    
DOI: 10.1007/s00381-011-1439-4     Document Type: Article

References (19)

1. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784 (Pubitemid 44348499)
2. Lindsey JC, Anderton JA, Lusher ME, Clifford SC (2005) Epigenetic events in medulloblastoma development. Neurosurg Focus 19:E10
3. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC (2005) Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4:1912-1922 (Pubitemid 43056974)
4. Sonnemann J, Kumar KS, Heesch S, Müller C, Hartwig C, Maass M, Bader P, Beck JF (2006) Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 28:755-766
5. Furchert SE, Lanvers-Kaminsky C, Juürgens H, Jung M, Loidl A, Frühwald MC (2007) Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 120:1787-1794 (Pubitemid 46399367)
6. Kumar KS, Sonnemann J, Hong le TT, Buurman C, Adler F, Maass M, Völker U, Beck JF (2007) Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma. Anticancer Res 27:465-470 (Pubitemid 46363367)
7. Spiller SE, Ditzler SH, Pullar BJ, Olson JM (2008) Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 87:133-141
8. Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang CC, Kinyamu H, Lu N, Gao X, Leng Y, Chuang DM, Zhang W, Lu RB, Hong JS (2008) Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Neuropsychopharmacology 11:1123-1134
9. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM (2009) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14:51-59
10. Kim HJ, Leeds P, Chuang DM (2009) The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem 110:1226-1240
11. Desmet CJ, Peeper DS (2006) The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? Cell Mol Life Sci 63:755-759
12. Schmidt AL, de Farias CB, Abujamra AL, Kapczinski F, Schwartsmann G, Brunetto AL, Roesler R (2010) BDNF and PDE4, but not the GRPR, regulate viability of human medulloblastoma cells. J Mol Neurosci 40:303-310
13. Li XN, Parikh S, Shu Q, Jung HL, Chow CW, Perlaky L, Leung HC, Su J, Blaney S, Lau CC (2004) Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res 10:1150-1159 (Pubitemid 38198917)
14. Wegener D, Deubzer HE, Oehme I, Milde T, Hildmann C, Schwienhorst A, Witt O (2008) HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. Anticancer Drugs 19:849-857
15. Schmidt AL, Brunetto AL, Schwartsmann G, Roesler R, Abujamra AL (2010) Recent therapeutic advances for treating medulloblastoma: focus on new molecular targets. CNS Neurol Disord Drug Targets 9:335-348
16. dos Santos MP, Schwartsmann G, Roesler R, Brunetto AL, Abujamra AL (2009) Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells. Leuk Res 33:218-221
17. He XM, Skapek SX, Wikstrand CJ, Friedman HS, Trojanowski JQ, Kemshead JT, Coakham HB, Bigner SH, Bigner DD (1989) Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. J Neuropathol Exp Neurol 48:48-68 (Pubitemid 19018681)
18. Tamura K, Shimizu K, Yamada M, Okamoto Y, Matsui Y, Park KC, Mabuchi E, Moriuchi S, Mogami H (1989) Expression of major histocompatibility complex on human medulloblastoma cells with neuronal differentiation. Cancer Res 49:5380-5384 (Pubitemid 19240478)
19. Zavarella S, Nakada M, Belverud S, Coniglio SJ, Chan A, Mittler MA, Schneider SJ, Symons M (2009) Role of Rac1-regulated signaling in medulloblastoma invasion. Laboratory investigation. J Neurosurg Pediatr 4:97-104